Autonomix Medical, Inc. (AMIX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 2.73M | 3.34M | 7.53M | 3.42M | 3.25M | 2.75M | 2.84M | 2.75M | 2.42M | 2.92M | 5.82M | 871K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.28M | 1.62M | 5.17M | 1.83M | 1.7M | 1.7M | 1.66M | 1.8M | 1.57M | 2.24M | 793K | 503K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.46M | 1.72M | 2.37M | 1.59M | 1.55M | 1.04M | 1.17M | 954K | 841K | 687K | 471K | 368K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 0 |
| Operating Income | -2.74M | -3.34M | -7.53M | -3.42M | -3.25M | -2.75M | -2.84M | -2.75M | -2.42M | -2.92M | -5.82M | -871K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 15.84% | -21.7% | -165.66% | -24.26% | -34.6% | 6.05% | 51.27% | -216.07% | -267.73% | - | - | -120.95% |
| EBITDA | -2.73M | -3.34M | -7.53M | -3.42M | -3.2M | -2.7M | -2.79M | -2.71M | -2.37M | -2.89M | -4.56M | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 14.67% | -23.67% | -169.87% | -26.13% | -35.19% | 6.54% | 38.74% | - | - | - | - | - |
| D&A (Non-Cash Add-back) | 3K | 4K | 2K | 3K | 48K | 47K | 45K | 43K | 46K | 35K | 1.26M | 871K |
| EBIT | -2.74M | -3.26M | -7.45M | -3.34M | -3.15M | -2.67M | -2.76M | -2.66M | -5.36M | -3.08M | -6.04M | -865K |
| Net Interest Income | 71K | 82K | 83K | 84K | 61K | 35K | 29K | 54K | 34K | -10K | 19K | 6K |
| Interest Income | 71K | 82K | 83K | 84K | 107K | 80K | 72K | 95K | 80K | 23K | 19K | 6K |
| Interest Expense | 0 | 0 | 0 | 0 | 46K | 45K | 43K | 41K | 46K | 33K | 0 | 0 |
| Other Income/Expense | 71K | 82K | 83K | 84K | 61K | 35K | 29K | 54K | -2.99M | -189K | -220K | 6K |
| Pretax Income | -2.67M | -3.26M | -7.45M | -3.34M | -3.19M | -2.71M | -2.81M | -2.7M | -5.41M | -3.11M | -6.04M | -865K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.67M | -3.26M | -7.45M | -3.34M | -3.19M | -2.71M | -2.81M | -2.7M | -5.41M | -3.11M | -6.04M | -865K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 16.45% | -20.24% | -165.44% | -23.64% | 40.99% | 12.88% | 53.53% | -212.02% | -723.14% | - | - | -119.43% |
| Net Income (Continuing) | -2.67M | -3.26M | -7.45M | -3.34M | -3.19M | -2.71M | -2.81M | -2.7M | -5.41M | -3.11M | -6.04M | -865K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.83 | -7.56 | -28.98 | -22.47 | -38.01 | -30.66 | -51.87 | -2.94 | -6.09 | -3.57 | -120.12 | -0.96 |
| EPS Growth % | 87.29% | 75.34% | 44.13% | -664.29% | -524.14% | -758.82% | 56.82% | -205.01% | -728.57% | - | - | 93.05% |
| EPS (Basic) | -4.83 | -7.56 | -28.98 | -22.47 | -38.01 | -30.66 | -51.87 | -2.94 | -6.09 | -3.57 | -120.12 | -0.96 |
| Diluted Shares Outstanding | 543.3K | 426.47K | 257.7K | 147.87K | 84.11K | 88.19K | 54.14K | 900.1K | 897.43K | 894.95K | 634.81K | 897.43K |
| Basic Shares Outstanding | 543.3K | 426.47K | 257.7K | 147.87K | 84.11K | 88.19K | 54.14K | 900.1K | 897.43K | 894.95K | 634.76K | 897.43K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |